Subject(s)
Endocarditis, Bacterial/complications , Endocarditis, Bacterial/prevention & control , Antibiotic Prophylaxis/classification , Antibiotic Prophylaxis/statistics & numerical data , Antibiotic Prophylaxis/instrumentation , Dental Care for Chronically Ill/methods , Dental Care for Chronically Ill , Cardiovascular Diseases/complications , Cardiovascular Diseases/therapyABSTRACT
Group B Streptococcus is an important cause of maternal and neonatal morbidity and mortality in many parts of the world. The last two decades have seen intensified efforts in the Western hemisphere in the prevention of this devastating infection by identifying and treating pregnant women who carry group B streptococci or who are at highest risk of transmitting the organism to newborns. The intrapartum use of antibiotics in these women has led unequivocally to a decrease in the rate of neonatal group B streptococcal disease. Although studies in India show a predominance of Gram negative bacterial sepsis among infants, contributing to infant mortality, it is possible that the role of group B Streptococcus has been underestimated. This review discusses its epidemiology in India, and summarizes current concepts of microbiology, pathogenesis, clinical management and preventative issues regarding group B streptococcal disease.